Boston Scientific Launches $2B Accelerated Buyback, Secures 30.4M Shares
Boston Scientific entered a $2B accelerated share repurchase with JPMorgan, receiving about 30.4M shares (80% of the price at the $52.68 closing price) as part of its $5B buyback program. It expects $0.02 EPS accretion in 2026 and will have $3B remaining authorization after ASR completes June 30.
1. ASR Agreement Terms
Boston Scientific entered an accelerated share repurchase agreement with JPMorgan Chase Bank to repurchase $2 billion of its common stock as part of its $5 billion buyback authorization.
2. Share Allocation and Pricing
Under the ASR, Boston Scientific will pay the $2 billion repurchase price and receive common stock equal to 80% of that value based on the $52.68 closing share price on May 15, representing approximately 30.4 million shares. The ultimate number of shares repurchased will be determined by the volume-weighted average price during the ASR term, less a contractual discount.
3. EPS Impact and Timeline
The ASR is expected to finalize by June 30, 2026 and deliver $0.02 of adjusted earnings per share accretion in full-year 2026, modestly enhancing the company's prior guidance.
4. Remaining Authorization
Following completion of the ASR, Boston Scientific will have $3 billion remaining under its $5 billion share repurchase authorization.